Chronic Lymphocytic Leukemia New Reference: Zanubrutinib for Treatment-Naive CLL Ulas D. Bayraktar, MD 2025-03-14
Skeletal Sarcoma New Drug: Vemseltinib for Tenosynovial Giant Cell Tumor Ulas D. Bayraktar, MD 2025-03-14
Non-Small Cell Lung Cancer New Drug: Ivonescimab for PD-L1 Positive NSCLC Ulas D. Bayraktar, MD 2025-03-14
Nasopharyngeal Cancer New Protocol: Pembrolizumab and Bevacizumab for Nasopharyngeal Cancer Ulas D. Bayraktar, MD 2025-03-02
Hepatocellular Carcinoma New Reference: Lenvatinib and Pembrolizumab for HCC Ulas D. Bayraktar, MD 2025-03-02
Non-Small Cell Lung Cancer New Protocol: Osimertinib with Ramucirumab for EGFR-Mutated NSCLC Ulas D. Bayraktar, MD 2025-03-02
Mantle cell lymphoma New Indication: Ibrutinib with Venetoclax for Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2025-03-02
Head and Neck Cancer New Indication: Enfortumab Vedotin for Head and Neck Cancer Ulas D. Bayraktar, MD 2025-03-02
Chronic Lymphocytic Leukemia New Protocol: Acalabrutinib + Venetoclax for Fixed Duration with/without Obinutuzumab Ulas D. Bayraktar, MD 2025-02-07
Non-Small Cell Lung Cancer New Reference: Zenocutuzumab for NRG1 Fusion-Positive Cancer Ulas D. Bayraktar, MD 2025-02-07
